

Our ref: IG/FOI/FOI.022.26

21 January 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

## **Request under the Freedom of Information Act 2000**

I write further to your request for information which was received on 14 January 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

### Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information: FOI Request: Acute Myeloid Leukaemia (AML) Patients.

Q1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months.

- a. Of these patients how many are refractory/ relapsed (R/R)?
- b. How many of the R/R patients were FLT3 positive?

Q2. How many patients have been treated for AML in the latest 12 months with the following treatments

- Venetoclax with azacitidine
- Midostaurin
- Quizartinib
- Gemtuzumab
- Ivosidenib with azacitidine
- Liposomal cytarabine–daunorubicin
- Oral azacitidine
- Gilteritinib
- Palliative care
- Enrolled in a clinical trial

Q3 How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments

administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use).

- Venetoclax with azacitidine
- Midostaurin
- Quizartinib
- Gemtuzumab
- Ivosidenib with azacitidine
- Liposomal cytarabine–daunorubicin
- Oral azacitidine
- Gilteritinib
- Palliative care
- Enrolled in a clinical trial

Q4. Of your AML patient how many were tested as below in the last 12 months

- Received an FLT3 mutation test when they were diagnosed
- Received an FLT3 mutation test when their disease relapsed
- Received an FLT3 mutation test when their disease became refractory

Powys Response:

I can confirm that Powys Teaching Health Board (PTHB) does not directly diagnose, treat or test patients for Acute Myeloid Leukaemia (AML). PTHB is a non-acute care provider, and therefore does not directly provide these services. Patients are treated by providers outside of Powys. PTHB commissions services from a number of Welsh health boards and English provider organisations.

Due to the complex nature of PTHB’s commissioning arrangements, not all of our providers indicate the indication for use for each episode of care where these drugs are used. For this reason, PTHB does not hold the data relating to your request, however, the health board is working closely with providers to ensure that this information can be provided in the future. We therefore recommend that you approach our provider organisations directly for this information. The table below lists the main health boards and NHS Trust from which we commission health services for Powys residents. Please note that all providers may not necessarily offer services that fall within the definition in your request.

<b>Health Trust/Organisation</b>	<b>FOI Contact Details</b>
Gloucestershire Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
The Shrewsbury and Telford Hospital NHS Trust	sath.foi@nhs.net
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.Information@wvt.nhs.uk

<b>Health Board/Organisation</b>	<b>FOI Contact Details</b>
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk

Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University NHS Trust	Foi.vunhst@wales.nhs.uk

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: [www.ico.org.uk/foicomplaints](http://www.ico.org.uk/foicomplaints)

Web site: <https://ico.org.uk/>

### **Re-use of Public Sector Information**

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



**David Farnsworth**  
**Assistant Director, Community Services Group**



**Kate Wright**  
**Executive Medical Director**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.